Antibe Therapeutics Inc (ATBPF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 03/31
| 06-2021 | 03-2021 | 12-2020 | 09-2020 | 06-2020 | |
| Sales | 2,220 | 2,180 | 2,144 | 2,151 | 887 |
| Cost of Goods | 1,339 | 1,454 | 1,242 | 1,459 | 517 |
| Gross Profit | 881 | 727 | 902 | 692 | 370 |
| Operating Expenses | 6,364 | 5,866 | 5,702 | 7,090 | 4,435 |
| Operating Income | -5,143 | -4,685 | -4,558 | -5,939 | -3,548 |
| Interest Expense | 23 | 10 | 5 | 41 | -6 |
| Other Income | 38 | 10 | 10 | 9 | 6 |
| Pre-tax Income | -5,129 | -4,685 | -4,553 | -5,971 | -3,537 |
| Income Tax | N/A | N/A | N/A | N/A | 4 |
| Net Income Continuous | -5,129 | -4,682 | -4,553 | -5,971 | -3,540 |
| Net Income Discontinuous | N/A | -755 | -433 | N/A | N/A |
| Net Income | $-5,129 | $-5,436 | $-4,986 | $-5,971 | $-3,540 |
| EPS Basic Total Ops | -0.11 | -0.11 | -0.13 | -0.15 | -0.14 |
| EPS Basic Continuous Ops | -0.11 | -0.11 | -0.12 | -0.15 | -0.12 |
| EPS Basic Discontinuous Ops | N/A | -0.02 | -0.01 | N/A | N/A |
| EPS Diluted Total Ops | -0.11 | -0.11 | -0.13 | -0.15 | -0.14 |
| EPS Diluted Continuous Ops | -0.11 | -0.11 | -0.12 | -0.15 | -0.12 |
| EPS Diluted Discontinuous Ops | N/A | -0.02 | -0.01 | N/A | N/A |
| EBITDA(a) | $-5,064 | $-4,613 | $-4,475 | $-5,832 | $-3,449 |